Pathology: breast cancer - adjuvant; es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1); la/mBC - HR-positive - 1st line (L1);
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HR-positive - 1st line (L1) | ||||
| BCIRG-006 (TCH vs AC-T), 2011 | BCIRG-006 (AC-TH vs TCH), 2011 | BCIRG-006 (AC-TH vs AC-T), 2011 | GeparQuinto, 2012 | SYSUCC-002, 2022 | SYSUCC-002, 2022 | ||
| trastuzumab plus endocrine therapy | 2 | T1 | T1 | ||||
| doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab | 2 | T1 | T1 | ||||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | |||||
| docetaxel plus carboplatin with trastuzumab followed by trastuzumab | 1 | T1 | T0 | ||||
| trastuzumab plus chemotherapy | 0 | T0 | T0 | ||||
| lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 | |||||
| doxorubicin plus cyclophosphamide followed by docetaxel | 0 | T0 | T0 | ||||